Management Team

  • Darrin R. Uecker

    Chief Executive Officer, President & Director
    Darrin R. Uecker has been our Chief Executive Officer and President and a Director since September 2015. Mr. Uecker has over 25 years of experience in the medical device field and is a named inventor on over 70 patents. Prior to Pulse Biosciences Mr. Uecker was the President and Chief Operating Officer of Progyny, Inc., Menlo Park, California, a company that developed Eeva™, the world’s first automated time-lapse system for embryo selection during in-vitro fertilization. Prior to that Mr. Uecker was the Chief Executive Officer and President and a Director of Gynesonics, Inc., Redwood City, California, a company that developed a novel medical device for the treatment of symptomatic uterine fibroids using ultrasound guided radiofrequency ablation. Mr. Uecker has served in a variety of executive level roles at CyberHeart, Inc., Conceptus, Inc., RITA Medical Systems, Inc., and Computer Motion, Inc. Mr. Uecker attended the University of California at Santa Barbara where he received a B.S. and M.S. in electrical and computer engineering.
    • Ed Ebbers

      Executive Vice President and General Manager, Dermatology
      Ed Ebbers joined Pulse Biosciences in August 2016 as Vice President and General Manager of the Dermatology franchise. Mr. Ebbers brings more than 35 years of senior leadership and general management experience with major dermatology, pharmaceutical and device brands including Zeltiq Aesthetics, Thermage, and Penederm Dermatologics. In these roles, he led worldwide product development, marketing and sales. At Pulse Biosciences, he manages the development of the dermatology franchise for the Company’s Nano-Pulse Stimulation technology. Mr. Ebbers holds a BBA from the University of Wisconsin, Eau Claire, and a MBA from the University of Minnesota, Carlson School of Management.
      • Sandra A. Gardiner

        Executive Vice President and Chief Financial Officer
        Sandra A. Gardiner joined Pulse Biosciences in November 2019 as Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer. Ms. Gardiner brings more than 30 years of experience in the life science industry, with 20 years specifically in the medical device field across multiple market segments. Prior to joining Pulse Biosciences, Ms. Gardiner served as Executive Vice President and Chief Financial Officer of Cutera, Inc., a global provider of laser, light and other energy-based aesthetic systems. Previous to that, Ms. Gardiner served as Vice President and Chief Financial Officer of Tria Beauty, Inc., a medical device manufacturer of laser based aesthetic devices. Ms. Gardiner’s other past held roles include a series of Vice President and Chief Financial Officer positions with both publicly traded and privately held companies, including Asante Solutions, Aptus Endosystems, Ventus Medical, Vermillion and Lipid Sciences.  Ms. Gardiner earned her B.A. in Management Economics from the University of California, Davis.
        • Mitchell E. Levinson

          Chief Strategy Officer
          Mitchell E. Levinson joined as Chief Strategy Officer of Pulse Biosciences in August 2021 and continues in his role on our Board of Directors.  Mr. Levinson served on the board from January 2015 to November 2017 and then returned in March 2019. Mr. Levinson has over 30 years of experience developing and launching novel medical device technologies across multiple medical disciplines, including dermatology, wound care, surgery, diagnostics, otolaryngology, microbiology, neurology, OB/GYN, patient monitoring and digital health. Most recently, he co-founded and served as startup CEO for Cerebrotech Medical Systems where he led the development of a novel brain monitor. Mr. Levinson was the first employee and startup CEO for Zeltiq Aesthetics, the CoolSculpting company, acquired by Allergan in 2017. Prior to Zeltiq, he held executive R&D positions at Thermage and BioSurgical Corporation. Mr. Levinson currently sits on the boards of directors for several medical technology startup companies, including here at Pulse Biosciences. He is an inventor on 50 issued and numerous pending U.S. patents. Mr. Levinson earned his B.S. in Mechanical Engineering from University of California at San Diego and holds an M.S. in Computer Systems from the University of Phoenix.
          • Richard Nuccitelli, Ph.D.

            Chief Science Officer
            Richard Nuccitelli, Ph.D. has been our Chief Science Officer since November, 2014. He was a Professor of Molecular and Cellular Biology at UC Davis for 23 years. He left UC Davis in 2001 to form BioElectroMed and was half-time Professor at Old Dominion University from 2004-2007 where he worked with Karl Schoenbach and Stephen Beebe on the use of nanosecond pulsed electric fields. He was elected Fellow of the American Association for the Advancement of Science in 1995 and Fellow in the American Institute for Medical and Biological Engineering in 2015. He has 134 publications and 7 patents. Dr. Nuccitelli has both an M.S. degree in Physics and a Ph.D. in Biological Sciences from Purdue University.
            • David Danitz

              Senior VP of Engineering
              David Danitz joined Pulse Biosciences in November 2015 as VP of Engineering. Mr. Danitz has over 20 years of medical device development experience and is the named inventor on over 50 US patents. Prior to Pulse Biosciences he held the position of Vice President, R&D - Custom Products at Earlens, where he led the development of a light-driven transducer that directly engaged the ear drum to generate sound. Before that, Mr. Danitz held the position of Vice President R&D for Gynesonics, where he led the development of the world’s first intrauterine ultrasound system with integrated RF ablation for an incisionless treatment of uterine fibroids. Mr. Danitz also served at Novare Surgical as Vice President of R&D where for 10 years his team brought medical devices to the market in the areas of cardiac, vascular, general, urologic and gynecologic surgery. Mr. Danitz has received several Medical Design Excellence Award’s. Mr. Danitz earned a BSME degree with high honors from the University of California at Santa Barbara, and a SMME degree from the Massachusetts Institute of Technology.
              • Holly Hartman

                Vice President, Business Development and Corporate Strategy
                Holly Hartman, Ph.D., J.D. joined Pulse Biosciences in August 2016 as Vice President, Business Development and Corporate Strategy. Dr. Hartman brings to Pulse Biosciences more than 15 years in scientific and financial roles in the life sciences industry. Prior to joining Pulse, Dr. Hartman served as Director, Business Development / External R&D / Strategy & Corporate Development at Amgen, where she helped to identify and evaluate strategic opportunities and partnerships for multiple therapeutic areas including oncology. Dr. Hartman has also held various positions in investment banking working on life sciences transactions. Dr. Hartman earned her Ph.D. in comparative pathology with an emphasis in immunopathology, J.D. and B.A. in zoology all from the University of California, Davis.
                • William Knape

                  Vice President, Regulatory, Clinical and Quality Affairs
                  William Knape joined Pulse Biosciences in May 2018 as Vice President, Regulatory, Clinical, and Quality Affairs. Mr. Knape is an expert in regulatory affairs, clinical and quality assurance specializing in FDA and CE submissions with over 25 years working directly with the FDA in the life sciences industry, for both Rx and OTC products. His experience includes multiple regulatory submissions of 510(k)s, PMAs, IDEs, Pre-IDEs and Q-Sub meetings and international registration filings for a wide variety of innovative and novel medical device and IVD companies. Mr. Knape has managed numerous worldwide multicenter, clinical studies from first-in-man to Phase IV clinical programs. Prior to joining Pulse, Mr. Knape served in senior roles as Senior Director and Vice-President, where he helped develop key financial opportunities with strategic partners in multiple therapeutic areas including dermatology, oncology, aesthetics, diabetes, regenerative medicine, neurology, cardiology, and gastroenterology. Mr. Knape earned his B.Sc. in Psychology and B.Sc. in Medical Technology with an emphasis in bioengineering from the University of Wyoming and serves on the College of Health Sciences Advisory Board.
                  • Edison Manuel

                    Vice President of Operations
                    Edison Manuel joined Pulse Biosciences in April 2017 as VP of Operations. Mr. Manuel has over 30 years of experience and held several senior level positions with the last 22 years focused on medical devices ranging from robotics, RF ablation systems, motion hand-held laparoscopic instruments and time-lapse imaging system. Mr. Manuel brings extensive experience in operations from start-up manufacturing into full commercial release, program management, factory integration and consolidation, strategic outsourcing and supply chain management. Prior to joining Pulse, he held similar positions at Progyny, Stellartech Research Corp and Novare Surgical Systems. Mr. Manuel also held senior level positions RITA Medical Systems and Computer Motion, Inc. Mr. Manuel earned a B.S. degree in Management and Industrial Engineering at Mapua Institute of Technology, Manila, Philippines.
                    • Patty Perla

                      Vice President of Human Resources
                      Patty Perla joined Pulse Biosciences in March 2020 as Vice President of Human Resources.  Ms. Perla brings over 15 years of experience in human resources building diverse, high performing organizations in the life science industry.  Her expertise extends across the spectrum of human resources, including talent development, culture initiatives and innovative total rewards strategies.  Prior to joining Pulse, Ms. Perla has held various leadership roles with small and mid-size companies including Ceterix Orthopaedics (acquired by Smith and Nephew), Revance Therapeutics, Ventus Medical and FoxHollow Technologies (acquired by EV3).  Ms. Perla earned a B.S. degree in Management from Golden Gate University in San Francisco.
                      • Ken Stratton

                        General Counsel and Corporate Secretary
                        Ken Stratton, J.D., joined Pulse Biosciences in May 2021 as General Counsel and Corporate Secretary. Mr. Stratton brings more than 25 years of wide-ranging legal experience, including having led legal affairs at multiple publicly-traded life science companies. Prior to joining Pulse Biosciences, Mr. Stratton was General Counsel of StemCells, Inc., Deputy General Counsel of Threshold Pharmaceuticals, Inc., and Senior Legal Counsel at Medtronic’s Vascular Business Unit. As the senior most legal counsel, he has handled all aspects of life science law including compliance, IP licensing and commercial partnering. Prior to working in-house, Mr. Stratton was a corporate transactional attorney at Gibson Dunn & Crutcher, a leading global law firm, and an employment litigator at Littler Mendelson, the largest labor and employment law firm. Most recently, he was a Partner at Rogoway Law Group, a specialty life science firm. Mr. Stratton earned his undergraduate degrees from the University of Pennsylvania, his M.B.A. in Finance from the Stern School of Business at N.Y.U., and his J.D. from the New York University School of Law.
                        • Robert Tyson

                          Vice President of Sales, North America
                          Robert Tyson joined Pulse Biosciences in December 2018 to build and deploy a U.S. sales team. Mr. Tyson is a proven sales leader with over 20 years of medical device experience including a strong early foundation of more than 10 years with Ethicon-Endo Surgery and Edwards Heart Valve Therapy. Since 2003 Robert participated in launching several breakthrough aesthetic dermatology technologies while holding various sales leadership positions of increasing responsibility with Miramar Labs, Zeltiq Aesthetics, Ulthera, Reliant Technologies and Thermage, all of which featured utilization-based revenue models.